基石藥業-B(02616.HK):潛在全球同類最佳藥物CS5001(ROR1 ADC )I期臨牀在美國完成首例患者入組
格隆匯3月31日丨基石藥業-B(02616.HK)發佈公吿,CS5001已在美國完成I期臨牀試驗首例患者入組。這是基石藥業正在推進的管線2.0戰略的又一里程碑。作為全球研發最快之一的受體酪氨酸激酶樣孤兒受體1(receptor tyrosine kinase-like orphan receptor 1,“ROR1”)抗體偶聯藥物(“ADC”),CS5001已展示了其在多種惡性血液和實體腫瘤領域的治療潛力。
基石藥業首席科學官謝毅釗博士表示:“我們非常高興地看到CS5001在美國完成I期臨牀試驗完成首例患者入組。這一潛在全球同類最佳ROR1 ADC具有許多差異化特徵,包括全人源的抗體骨架,專有的位點特異性偶聯、腫瘤選擇性可切割連接子和前藥技術,這些特點轉化到臨牀中,可能具有更寬的治療視窗,有潛力應用於廣泛的癌症類型。從臨牀前的數據來看, CS5001對錶達ROR1的血液和惡性實體腫瘤領域的治療潛力擁有值得期待。我們將快速全面推進CS5001的全球同步開發,將通過全球臨牀試驗來研究其在晚期B細胞淋巴瘤和實體瘤中的安全和早期療效。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.